Study of Visceral Fat in type2diabetic Patients and Its Relation to Microvascular Complications

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-05

Study Completion Date

2025-06-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study the correlation between METS IR and visceral fat in type 2 diabetes and its relation to microvascular complication

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Intra-Abdominal Fat in Patients With Type 2 Diabetes Using a Non-Invasive Method

NCT01283113

Obesity Type 2 Diabetes Metabolic Syndrome

COMPLETED

Insulin Resistance and Severity of Coronary Artery Disease

NCT05215821

Insulin Resistance

UNKNOWN

Relationship Between Glycemic Control and Irisin in Type 2 Diabetic Patients With Sarcopenic or Non-sarcopenic Obesity

NCT05908812

Sarcopenia Obesity Diabetes Mellitus, Type 2

RECRUITING

THE Effect of Tight Glycemic Control on Microvascular Complications in Type 2 Diabetes Mellitus

NCT07049601

Diabetes Mellitus

COMPLETED NA

Cardiovascular Disease CVD Constitutes a Significant Health Challenge for Individuals With Type 2 Diabetes Mellitus T2DM, Affecting Approximately 32% of This Population and Contributing Significantly to Global Mortality.Visceral Adipose Tissue VAT Accumulation Has Been Recognize

NCT07204782

Diabete Mellitus

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Metabolic Score for Insulin Resistance (METS-IR) is a metabolic index developed with the aim to quantify peripheral insulin sensitivity in humans; it was first described under the name METS-IR by Bello-Chavolla et al in 2018. It was developed by the Metabolic Research Disease Unit at the Institute National de Ciencias Médicas Salvador Zubirán and validated against the euglycemic hyperinsulinemic clamp and the frequently-sampled intravenous glucose tolerance test in Mexican population.It is a non-insulin-based alternative to insulin-based methods to quantify peripheral insulin sensitivity and an alternative to the Homeostatic Model Assessment (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI).

Very limited research correlate between visceral obesity and microvascular complications in type 2 diabetic patients and how can the metabolic score for insulin resistance predict visceral obesity and microvascular complications in type2 diabetic patients. In this study the investigators will search for these correlations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Visceral Fat Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years Both male and female subjects Subjects capable of giving consent and voluntarily willing to participate in the study

Exclusion Criteria

* Chronic kidney disease patients Any nondiabetic nephropathy patients Patients affected by hypertension Patients affected by ocular disorders Neuropathies of other etiologies like chronic liver disease patients, alcoholics, or drug addicts Critically ill patients of type 2 diabetes mellitus Patients who have not given consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes